Increasing constitutional challenges to FTC adjudication could hasten Supreme Court review
Following Amgen and Horizon Therapeutics’ recent counterclaim against the Federal Trade Commission alleging that the agency’s in-house court violates the Constitution, a blueprint has emerged for dealmakers to challenge the constitutionality...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: